Thymulin is a nine-amino-acid hormone made by the epithelial cells of the thymus. Its sequence is Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, and it has one unusual property: the bare peptide does nothing on its own. It only becomes biologically active when a zinc ion binds to it in a one-to-one ratio. That zinc-loaded form is what people mean by "zinc thymulin."
The peptide was first described decades ago under the name facteur thymique sérique (FTS), or serum thymic factor. In its native role it helps T-lymphocytes mature, inside and outside the thymus, which is why most of the older literature treats it as an immune-regulating hormone rather than anything to do with hair.
Why the zinc matters
Zinc isn't an additive here. It's structural. When zinc binds the thymulin peptide, the molecule folds into a specific three-dimensional shape that the body's targets recognize. Strip the zinc out and you get apo-thymulin, which is inactive. A review by Dardenne and Pleau laid this out: zinc-deficient animals and people show reduced circulating thymulin activity, and adding zinc back restores it. The authors went as far as proposing that thymulin activity could serve as a sensitive readout of zinc status (Dardenne & Pleau, *Metal-Based Drugs*, 1994; PubMed).
That is the well-established part of the story. It is immunology, and it is solid.
The hair-loss claim is much newer and much thinner
The reason zinc thymulin shows up on peptide vendor sites has nothing to do with the immune system. It traces to a single line of work by Edward Russell Vickers.
A patent filed by Vickers and Clinical Stem Cells Pty Ltd (WO2017210726A1) claims that topical zinc thymulin reactivates dormant hair follicles by pushing them back into anagen, the active growth phase. The patent is specific on one point: it argues that thymulin alone does not do this, and that the externally supplied zinc complex is what makes the difference.
The supporting clinical data is one paper. Vickers published An Analysis of the Safety and Efficacy of Topical Zinc-Thymulin to treat Androgenetic Alopecia in Hair Therapy & Transplantation in 2017. The compound was made by standard Fmoc peptide synthesis and applied as a water-based scalp spray. The study followed 18 adults (17 men, one woman, ages 35 to 90) with androgenetic alopecia, over roughly four to ten months. Reported results were an increase of about 32% in vellus hair count and about 23% in intermediate hair count, with no systemic effects and no reports of scalp irritation (Vickers, *Hair Ther Transplant* 2017, 7:147).
Weigh that carefully. Eighteen people, a wide age spread, no control or placebo group described, and the lead author is also the patent holder. It is a small open-label case series, not a controlled trial. The immunology behind thymulin is real; the hair-regrowth evidence is preliminary and has not been replicated in larger independent studies.
Regulatory and quality notes
Zinc thymulin is not an approved drug. It is sold as a research chemical or made up by compounding pharmacies, and nothing here is medical or dosing advice. None of this is approved for human consumption in the way an FDA-cleared treatment would be.
For anyone evaluating a product, the buyer-side question is whether the vial contains what the label says. A nonapeptide synthesized by Fmoc chemistry, then complexed with zinc, leaves room for variation in peptide purity, in the actual zinc loading, and in concentration, the patent's spray was 0.0005% zinc thymulin, an extremely low figure that magnifies any error. A third-party certificate of analysis showing identity (mass spec) and purity (HPLC) is the only way to check, and independent reputation signals matter more here than usual given how little published data exists.
Bottom line
Two separate facts often get blurred together. Thymulin's zinc dependence and immune role are genuinely well documented. Its use for hair loss rests on one small uncontrolled study by the patent holder. Treat the first as established and the second as an early signal that has not yet been confirmed.